FRANKLIN LAKES, N.J.,
Feb. 13, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced an early access program
for the BD Resolve™ Single-Cell Gene Expression platform that has
the flexibility to capture and analyze hundreds to tens of
thousands of individual cells in a broad range of sizes and
types.
The platform includes reagents that can analyze both the whole
transcriptome and targeted or custom-designed gene-specific panels.
When paired with the BD FACSMelody™ flow cytometer for
cell sorting and enrichment, unwanted cells can be removed to both
improve data accuracy and reduce sequencing costs.
"We are studying the regulation of processes in the kidney,
which have customarily been challenging to do with current
technologies," said Dr. Vivek
Bhalla, assistant professor of medicine (nephrology) at the
Stanford University Medical Center.
"Our early work with the BD Resolve platform has allowed us to
sequence single cells from multiple samples at the same time,
radically saving us on cost and time. The level of precision is
also orders of magnitude better. It's not an overstatement – we are
advancing our work far beyond what we could do before."
Single-cell genomics stands to offer new developments in several
fields including immunology, oncology, immune-oncology and
developmental biology, but conventional methods for isolating
nucleic acids from an individual cell can present technical
challenges and be financially limiting. Researchers are often left
needing to compromise on performance, workflow simplicity and cell
throughput (due to cost of sequencing).
"BD has more than 30 years of experience in single-cell analysis
through its cell sorting and enrichment platforms - approaches that
are a natural complement for next-generation sequencing," said
Stephen Gunstream, vice president of
BD Genomics. "We have created a workflow that can enrich for viable
cells of interest, improve cell-type resolution, and significantly
reduce extraneous downstream costs due to unnecessary single-cell
sequencing."
The BD Resolve early access program and introduction at the
Advances in Genome Biology and Technology (AGBT) conference
accompanies the release of the new whole-genome protocol for the BD
CLiC™ library prep instrument. This new protocol fully automates
processes traditionally done manually. With the new protocol, the
BD CLiC platform prepares libraries with 1/5th of the input mass
and at 20 to 50 percent reduced cost per sample.
BD plans full commercial launch of the BD Resolve platform by
early fall 2017.
Meet BD at the AGBT conference to learn more about the BD
Resolve platform and the Difference of One:
- Attend the BD workshop on Tuesday, Feb.
14, at Noon in the Grand Ballroom
- Visit the BD Genomics gallery in Room #319 to see Data in New
Dimensions: Convergence of Art, Genomics and Bioinformatics
- Join events spotlighting the impact of BD Genomics
technologies, including multiple symposia and posters
BD Resolve and BD CLiC platforms are currently available for
research use only and not for diagnostic or therapeutic use. For
more information, contact BD at +1 650.665.2400.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has more than 40,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-announces-early-access-program-for-bd-resolve-single-cell-analysis-platform-300406038.html
SOURCE BD (Becton, Dickinson and Company)